trending Market Intelligence /marketintelligence/en/news-insights/trending/Qg9ZVIRq5wV5kdjzlhG_-w2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

ANI Pharmaceuticals acquires 23 generic drugs from China's Amerigen for $52.5M

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

ANI Pharmaceuticals acquires 23 generic drugs from China's Amerigen for $52.5M

ANI Pharmaceuticals Inc. acquired 23 generic products from privately held pharmaceutical company Amerigen Pharmaceuticals Ltd. for $52.5 million in cash.

The Baudette, Minn.-based pharmaceutical company, which develops and markets branded and generic medicines in the U.S., will also pay about $25 million to Amerigen over the next four years, ANI said in a Jan. 9 press release.

These payments will be tied to the annual gross profit generated by the acquired portfolio: 10 commercial products, three products with regulatory approval and that are launch-ready, four filed products, four in-development products, and a license to commercialize two approved products, ANI Pharmaceuticals said.